November 18, 2026
Health news, explained with evidence
LIVE

Study Sheds Light on RAMP3 Protein and Immune Suppression in Breast Cancer Models

❤️ Conditions & Care 2 min read 👁 4

A new study in mice published in the Journal of Translational Medicine investigates how the protein RAMP3 influences the tumor environment and impacts immunotherapy response.

Study Sheds Light on RAMP3 Protein and Immune Suppression in Breast Cancer Models❤️Conditions & Care

Photo: Medical Xpress

Key points

  • Shinshu University researchers studied the protein RAMP3 in mouse breast cancer models.
  • Mice lacking RAMP3 had smaller tumors, less lung spread, and higher levels of cancer-fighting T cells.
  • The study remains preclinical, and further research is required to test pharmacological RAMP3 inhibitors in humans.

Cancer immunotherapy relies on harnessing the body's natural defenses to combat malignant cells, yet this approach remains ineffective for a significant number of patients. Investigators at Shinshu University in Japan sought to understand why, focusing on the cellular environment surrounding tumors. Specifically, doctoral student Yan Zhang, Dr. Megumu Tanaka, Professor Takayuki Shindo, and their colleagues examined receptor activity-modifying protein 3 (RAMP3) and its role in stromal regulation.

By studying mouse breast cancer models, the research team compared outcomes between subjects with normal RAMP3 levels and those genetically lacking the protein. Mice without RAMP3 developed smaller primary tumors, experienced less metastasis to the lungs, and demonstrated improved overall survival. Further tissue analysis revealed that the absence of RAMP3 correlated with fewer immune-suppressive macrophages and an increased presence of cytotoxic CD8⁺ T cells capable of targeting cancer. The investigators also observed reduced activity in the IL-4/STAT6 signaling pathway and lower levels of CCL8, mechanisms typically associated with immune suppression. In an exploratory trial involving five mice per group, subjects lacking RAMP3 also showed enhanced benefits from anti-PD-1 immunotherapy treatment.

What to know: While these findings suggest that RAMP3 may contribute to tumor-promoting immune exclusion, the work was conducted primarily in mice and relies on genetic gene deletion rather than pharmacological drug inhibition. Furthermore, human data from The Cancer Genome Atlas showed associations with survival markers but cannot prove that targeting RAMP3 will benefit patients. Readers should consult qualified medical professionals for any personal health decisions.

Source Medical Xpress — medicalxpress.com/news/2026-11-tracks-ramp3-role-breast-cancer.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.